PROSIGHT MANAGEMENT LP
Q2 2022 Form 13-F
DALLAS, TEXAS
CIK 0001617201
· CRD 148791
· SEC-registered investment adviser
$126.9M Reported Value Total
PROSIGHT CAPITAL reports 4 total accounts under management (AUM). There are 4 discretionary accounts valued at $256,405,000, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
2 funds
· $277.6M gross asset value
Hedge Fund: $277.6M
Source: Form ADV filed 2026-03-30
Reported value
$126.9M
Quarter over quarter
-25.1%
Holdings
23
Top-10 concentration
74.7%
Filing Structure
Reports holdings for
- West Tower Group LLC · File #028-23035 · Q1 2024 – Q1 2026 · declared by one filing
Holdings reported by
- APOGEM CAPITAL LLC · Q4 2020 – Q3 2022 · declared by one filing
- PA Capital LLC · Q4 2018 – Q3 2020 · declared by one filing
Key People
Form ADV owners & control persons
William Lawrence Hawkins
SOLE MEMBER / MANAGING PARTNER
Ryan Matthew Cappelli
CHIEF COMPLIANCE OFFICER / CHIEF OPERATING OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q2 2022 13F record
Q2 2022 13F filing summary
| Period of report | June 30, 2022 |
|---|---|
| Filed | August 12, 2022 |
| Form | 13F-HR |
| Reported value | $126.9M |
| Positions | 23 |
| Change in reported value | -18.1% |
| New positions | 7 |
| Exited positions | 14 |
| Position turnover | 56.8% |
| Top-10 concentration | 74.7% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
36 | $580.4M |
|
Q1 2026 13F
Filed May 15, 2026
|
46 | $609.8M |
|
Q4 2025 13F
Filed Feb 13, 2026
|
38 | $483.9M |
|
Q3 2025 13F
Filed Nov 14, 2025
|
41 | $428.8M |
|
Q2 2025 13F
Filed Aug 14, 2025
|
39 | $410.1M |
|
Q1 2025 13F
Filed May 15, 2025
|
38 | $304.3M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
35 | $361.8M |
|
Q3 2024 13F
Filed Nov 14, 2024
|
41 | $406.4M |
|
Q2 2024 13F
Filed Aug 14, 2024
|
46 | $334.6M |
|
Q1 2024 13F
Filed May 15, 2024
|
44 | $359.5M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
34 | $249.1M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
41 | $315.5M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
35 | $341.6M |
|
Q1 2023 13F
Filed May 12, 2023
|
39 | $210.9M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
37 | $183.4M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
36 | $186.7M |
|
Q2 2022 13F
Filed Aug 12, 2022
|
23 | $126.9M |
|
Q1 2022 13F
Filed May 16, 2022
|
30 | $154.9M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
32 | $167.0M |
|
Q3 2021 13F
Filed Nov 12, 2021
|
40 | $181.8M |
15 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q2 2022
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | LKFT GALAPAGOS NV | $20.6M | 16.22% |
| 2 | PRTA PROTHENA CORP PLC | $14.9M | 11.77% |
| 3 | KZR KEZAR LIFE SCIENCES INC | $10.4M | 8.23% |
| 4 | ALBO ALBIREO PHARMA INC | $9.3M | 7.32% |
| 5 | KALV KALVISTA PHARMACEUTICALS INC | $8.1M | 6.36% |
| 6 | ALDX ALDEYRA THERAPEUTICS INC | $7.9M | 6.24% |
| 7 | MGTX MEIRAGTX HLDGS PLC | $7.5M | 5.88% |
| 8 | CRL CHARLES RIV LABS INTL INC | $5.9M | 4.64% |
| 9 | ONEM 1LIFE HEALTHCARE INC | $5.7M | 4.48% |
| 10 | QDEL QUIDELORTHO CORP | $4.5M | 3.57% |
| 11 | STTK SHATTUCK LABS INC | $4.1M | 3.26% |
| 12 | CUE CUE BIOPHARMA INC | $4.1M | 3.25% |
| 13 | RCKT ROCKET PHARMACEUTICALS INC | $3.8M | 3.0% |
| 14 | 68269G907 C 1LIFE HEALTHCARE INC | $3.5M | 2.72% |
| 15 | GBT GLOBAL BLOOD THERAPEUTICS IN | $3.3M | 2.56% |
| 16 | MIRM MIRUM PHARMACEUTICALS INC | $3.1M | 2.48% |
| 17 | THC TENET HEALTHCARE CORP | $2.7M | 2.1% |
| 18 | BCRX BIOCRYST PHARMACEUTICALS INC | $1.9M | 1.47% |
| 19 | SPRY SILVERBACK THERAPEUTICS INC | $1.4M | 1.14% |
| 20 | PRQR PROQR THRAPEUTICS N V | $1.3M | 1.05% |
Values as reported on the Q2 2022 Form 13F. Every position is in the holdings table below.